GMAB Stock Analysis: Genmab AS | NASDAQ

Antibody Therapeutics, Oncology, Hematology, Immunotherapy

Total Rating 46

Safety 19

Buy Signal 0.13

Biotechnology
Industry Rotation: -2.2

Market Cap: 19.3B
Avg Turnover: 57.9M

Risk 3d forecast

Volatility34.6%

VaR 5^th Pctl6.17%

VaR vs Median8.21%

Reward TTM

Sharpe Ratio1.07

Rel. Str. IBD68.3

Rel. Str. Peer Group38.8

Character TTM

Beta0.555

Beta Downside0.556

Hurst Exponent0.531

Drawdowns 3y

Max DD54.12%

CAGR/Max DD-0.07

CAGR/Mean DD-0.12

EPS (Earnings per Share)

EPS CAGR: 27.60%
EPS Trend: 73.7%

Last SUE: 0.76
Qual. Beats: 0

Revenue

Rev. CAGR: -42.76%
Rev. Trend: -84.5%

Last SUE: -0.83
Qual. Beats: 0

Warnings

Beneish M-Score Likely Earnings Manipulation

Tailwinds

Confidence

Seasonality 11.6 years of data

Jan -5.3% 34

Feb -2.5% 19

Mar -0.1% 5

Apr +1.0% 5

May +3.1% 31

Jun +1.0% 8

Jul +7.3% 41

Aug +1.2% 14

Sep -8.1% 52

Oct -6.8% 44

Nov +6.3% 28

Dec -2.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: GMAB Genmab AS

Genmab A/S is a Danish biotechnology company founded in 1998 and headquartered in Copenhagen, specializing in the development of antibody-based therapeutics primarily for cancer and other serious diseases. The company markets EPKINLY/TEPKINLY (epcoritamab) for relapsed/refractory B-cell lymphomas and Tivdak for recurrent/metastatic cervical cancer, while generating additional revenue through commercialized products developed with partners, including DARZALEX (multiple myeloma), RYBREVANT (lung cancer), TECVAYLI and TALVEY (multiple myeloma), Kesimpta (multiple sclerosis), and TEPEZZA (thyroid eye disease).

Genmab maintains a broad pipeline spanning hematologic malignancies, solid tumors, and rare diseases, with notable candidates including Rinatabart Sesutecan (ovarian cancer), Acasunlimab (NSCLC), tisotumab vedotin (solid tumors), and earlier-stage assets such as GEN1059, GEN1055, GEN1057, and GEN1286. The companys business model is heavily collaboration-driven, with active partnerships across the biopharma industry including AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Amgen, and Novo Nordisk.

As a large-cap biotech, Genmab operates in the antibody therapeutics segment of healthcare, an area characterized by high R&D investment, long development timelines, and reliance on licensing agreements and milestone/royalty income to supplement direct product sales. Its dual model of independent commercialization and partnered development allows it to share development risk while retaining upside from successful candidates.

Headlines to Watch Out For

DARZALEX royalties expand as multiple myeloma use grows
Epcoritamab label expansion into frontline B-cell lymphomas
Pipeline readouts for acasunlimab in NSCLC drive upside

Piotroski VR-10 (Strict) 5.0

Net Income: 788.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -33.20 > 1.0
NWC/Revenue: 40.21% < 20% (prev 25.21%; Δ 15.00% < -1%)
CFO/TA 0.07 > 3% & CFO 890.3m > Net Income 788.1m
Net Debt (3.91b) to EBITDA (1.43b): 2.74 < 3
Current Ratio: 2.46 > 1.5 & < 3
Outstanding Shares: last quarter (617.1m) vs 12m ago -0.45% < -2%
Gross Margin: 93.03% > 18% (prev 94.83%; Δ -1.80% > 0.5%)
Asset Turnover: 43.54% > 50% (prev 201.3%; Δ -157.8% > 0%)
Interest Coverage Ratio: 4.95 > 6 (EBIT TTM 1.33b / Interest Expense TTM 269.3m)

Altman Z'' 3.92

A: 0.13 (Total Current Assets 2.80b - Total Current Liabilities 1.14b) / Total Assets 12.5b
B: 0.35 (Retained Earnings 4.42b / Total Assets 12.5b)
C: 0.14 (EBIT TTM 1.33b / Avg Total Assets 9.49b)
D: 0.91 (Book Value of Equity 5.96b / Total Liabilities 6.56b)
Altman-Z'' = 3.92 = AA

Beneish M -1.17

DSRI: 3.0 (Receivables 1.28b/997.8m, Revenue 4.13b/13.0b)
GMI: 1.02 (GM 94.83% / 93.03%)
AQI: 2.15 (AQ_t 0.76 / AQ_t-1 0.35)
SGI: 0.32 (Revenue 4.13b / 13.0b)
TATA: -0.01 (NI 788.1m - CFO 890.3m) / TA 12.5b)
Beneish M = -1.17 (Cap -4..+1) = D

What is the price of GMAB shares?

As of August 18, 2026, the stock is trading at USD 32.84 with a total of 3,431,957 shares traded. Over the past week, the price has changed by +6.38%, over one month by +14.35%, over three months by +24.54% and over the past year by +40.22%.

Current recommended Stop Loss: 31.50 (which is 4.1% or 1.6 ATR below the current price).

Is GMAB a buy, sell or hold?

Genmab AS has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy GMAB.

StrongBuy: 4
Buy: 1
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the GMAB price?

Analysts Target Price	38.7	17.9%

Genmab AS (GMAB) - Fundamental Data Overview as of 14 August 2026

Market Cap USD = 19.3b (19.3b USD * 1.0 USD.USD)
P/E Trailing = 24.3566
P/E Forward = 17.9856
P/S = 4.7425
P/B = 3.2312
P/EG = 2.0269
Revenue TTM = 4.13b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 1.43b USD
Long Term Debt = 4.84b USD (from longTermDebt, last quarter)
Short Term Debt = 312.0m USD (from shortTermDebt, last quarter)
Debt = 5.41b USD (from shortLongTermDebtTotal, last quarter) + Leases 138.0m
Net Debt = 3.91b USD (calculated: Debt 5.41b - CCE 1.50b)
Enterprise Value = 23.2b USD (19.3b + Debt 5.41b - CCE 1.50b)
Interest Coverage Ratio = 4.95 (Ebit TTM 1.33b / Interest Expense TTM 269.3m)
EV/FCF = 26.77x (Enterprise Value 23.2b / FCF TTM 867.3m)
FCF Yield = 3.74% (FCF TTM 867.3m / Enterprise Value 23.2b)
FCF Margin = 21.00% (FCF TTM 867.3m / Revenue TTM 4.13b)
Net Margin = 19.08% (Net Income TTM 788.1m / Revenue TTM 4.13b)
Gross Margin = 93.03% ((Revenue TTM 4.13b - Cost of Revenue TTM 288.0m) / Revenue TTM)
Gross Margin QoQ = 92.73% (prev 92.75%)
Tobins Q-Ratio = 1.86 (Enterprise Value 23.2b / Total Assets 12.5b)
Interest Expense / Debt = 4.98% (Interest Expense 269.3m / Debt 5.41b)
Taxrate = 13.02% (118.0m / 906.1m)
NOPAT = 1.16b (EBIT 1.33b * (1 - 13.02%))
Current Ratio = 2.46 (Total Current Assets 2.80b / Total Current Liabilities 1.14b)
Debt / Equity = 0.91 (Debt 5.41b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 2.74 (Net Debt 3.91b / EBITDA 1.43b)
Debt / FCF = 4.51 (Net Debt 3.91b / FCF TTM 867.3m)
Total Stockholder Equity = 5.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 788.1m / Total Assets 12.5b)
RoE = 13.57% (Net Income TTM 788.1m / Total Stockholder Equity 5.81b)
RoCE = 12.53% (EBIT 1.33b / Capital Employed (Equity 5.81b + L.T.Debt 4.84b))
RoIC = 10.11% (NOPAT 1.16b / Invested Capital 11.5b)
WACC = 7.14% (E(19.3b)/V(24.7b) * Re(7.93%) + D(5.41b)/V(24.7b) * Rd(4.98%) * (1-Tc(0.13)))
Discount Rate = 7.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.66 | Cagr: -2.72%
[DCF] Terminal Value 73.10% ; FCFF base≈1.56b ; Y1≈1.37b ; Y5≈1.10b
[DCF] Fair Price = 22.47 (EV 17.7b - Net Debt 3.91b = Equity 13.8b / Shares 614.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 73.70 | EPS CAGR: 27.60% | SUE: 0.76 | # QB: 0
Revenue Correlation: -84.51 | Revenue CAGR: -42.76% | SUE: -0.83 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.35 | Chg30d=+10.12% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=1.16 | Chg30d=+10.22% | Revisions=+40% | GrowthEPS=-24.8% | GrowthRev=+23.4%
EPS next Year (2027-12-31): EPS=1.83 | Chg30d=+0.58% | Revisions=+40% | GrowthEPS=+57.9% | GrowthRev=+16.1%
[Analyst] Revisions Ratio: +67% (up=6, down=0)